Table 1 Clinical and hematologic characteristics of patients and univariable association to post-CABG adverse events

60.9 ± 10.3

60.4 ± 10.6

63.4 ± 8.5

0.111^*

168 (82.0%)

142 (84.5%)

26 (70.3%)

0.041^†

129 (62.9%)

103 (61.3%)

26 (70.3%)

0.307^†

112 (54.6%)

94 (56.0%)

18 (48.6%)

0.419^†

73 (35.6%)

61 (36.3%)

12 (32.4%)

0.656^†

35 (17.1%)

28 (16.7%)

7 (18.9%)

0.742^†

55.0 (50.0-60.0)

55.0 (50.0-60.0)

50.0 (45.0-55.0)

0.010^‡

0.011^†

146 (71.2%)

126 (75.0%)

20 (54.1%)

59 (28.8%)

42 (25.0%)

17 (45.9%)

0.93 (0.67-1.51)

0.84 (0.62-1.41)

1.31 (0.85-1.86)

0.001^‡

0.93 (0.80-1.07)

0.94 (0.81-1.08)

0.90 (0.74-0.99)

0.307^‡

94.4 ± 33.5

95.0 ± 34.5

92.1 ± 28.7

0.634^*

14.4 ± 1.6

14.6 ± 1.5

13.4 ± 1.5

<0.001^*

43.5 ± 5.2

44.1 ± 5.3

40.6 ± 4.2

<0.001^*

89.1 ± 4.9

89.1 ± 5.1

89.3 ± 4.1

0.848^*

29.7 ± 1.9

29.7 ± 1.9

29.6 ± 1.8

0.722^*

13.6 (13.1-14.2)

13.5 (13.1-14.2)

13.6 (13.1-14.3)

0.274^‡

268 ± 67

270 ± 67

262 ± 66

0.502^*

8.50 ± 0.78

8.44 ± 0.76

8.80 ± 0.80

0.009^*

8.27 ± 1.93

8.29 ± 2.00

8.17 ± 1.63

0.741^*

5.24 ± 1.64

5.23 ± 1.67

5.25 ± 1.48

0.955^*

2.16 ± 0.69

2.19 ± 0.68

2.03 ± 0.72

0.211^*

2.32 (1.86-3.19)

2.30 (1.81-3.15)

2.61 (1.95-3.52)

0.228^‡

96.7 ± 36.0

93.0 ± 35.1

113.8 ± 35.5

0.001^*

64.0 ± 25.5

62.9 ± 26.2

69.2 ± 21.8

0.173^*

3.0 (3.0-4.0)

3.0 (2.0-4.0)

4.0 (3.0-4.0)

0.018^‡

1 (1–2)

1 (1–2)

3 (1–6)

<0.001^‡

6 (5–7)

6 (5–7)

9 (7–18)

<0.001^‡